Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68.13 million versus the consensus estimate of $61.4 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.